Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides
摘要:
Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.
NOVEL ORGANIC COMPOUND, NEAR-INFRARED FLUORESCENT CONSTANT MEDIUM CONTAINING SAME, AND METHOD FOR NANO-GRANULATING CONSTANT MEDIUM
申请人:COLLEGE OF MEDICINE POCHON CHA UNIVERISTY INDUSTRY- ACADEMIC COOPERATION FOUNDATION
公开号:US20180327357A1
公开(公告)日:2018-11-15
The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.
A chiral-phosphoric-acid-catalyzed enantioselective cycloaddition-elimination cascade reaction was developed to access chiral azahelicenoid skeletons. This convergent approach offers an organocatalytic helicoselective route to obtain indolohelicenoids with high enantioselectivity. The prepared indolohelicenoids display positive photophysical and chiroptical properties, showcasing their potential utility
efficient catalytic asymmetric Michael-type reaction of azonaphthalenes with 5-aminoisoxazoles has been developed. The reaction was based on the utilization of a chiralphosphoricacid as the catalyst, delivering a large panel of axiallychiral heterobiaryl diamines in generally good yields with excellent enantioselectivities. The gram-scale reaction and postmodification of the chiral product demonstrated